TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab Govitecan (IMMU-132) In Patients With Advanced Urothelial Cancer

TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab Govitecan (IMMU-132) In Patients With Advanced Urothelial Cancer

Annual-Meeting

6 months
178 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab Govitecan (IMMU-132) In Patients With Advanced Urothelial Cancer. BACKROUND: Patients (pts) with advanced urothelial cancer (UC) who progress after checkpoint inhibitor (CPI) therapy (following failure of or ineligibility for platinum-based chemotherapy) have limited options. Trop-2 is an epithelial cell surface antigen overexpressed in UC (Avellini. Oncotarget 2017). Sacituzumab govitecan (SG) is an antibody-drug conjugate that targets Trop-2 and delivers the active metabolite SN38 of the topoisomerase I inhibitor irinotecan to tumor cells (Starodub. Clin Cancer Res 2015). In a phase 1/2 trial, pts with advanced cancers received SG on days 1 and 8 of a 21-day cycle. In the UC cohort, 45 evaluable pts received SG 10 mg/kg with a median of 2 (range 16) prior therapies. Objective response rate (ORR) was 31%; median duration of response was 12.9 mo. Grade ?3 adverse events in ?5% of pts were neutropenia/neutrophil count decreased (38%), anemia (13%), hypophosphatemia (11%), diarrhea (9%), fatigue (9%), and febrile neutropenia (7%). Median progression-free survival (PFS) was 7.3 mo and overall survival (OS) 16.3 mo (Tagawa 2019 ASCO Genitourinary Cancers Symposium). These results warrant further investigation in a dedicated phase 2 trial. METHODS: TROPHY-U-01 (NCT03547973) is a single-arm, global phase 2 trial evaluating the antitumor activity of SG (10 mg/kg on days 1 and 8 of a 21-day cycle) in 140 pts with advanced UC and measurable disease. Patients are also required to have an Eastern Cooperative Oncology Group Performance Status score of 0 or 1 and creatinine clearance ?30 mL/min. The pivotal cohort (Cohort 1: progression after both platinum chemotherapy and CPI) will enroll 100 evaluable pts in a Simon 2-stage design with > 90% power accounting for dropouts to exclude the null hypothesis or ORR < 12%; an exploratory cohort (Cohort 2: 40 pts) includes platinum-ineligible pts who progress after prior CPI. The primary objective is ORR per RECIST 1.1, assessed by central review. Secondary objectives include response duration, PFS, and OS. Adverse events, pharmacokinetics, and tissue correlates will also be assessed. Enrollment began August 2018. Clinical trial information: NCT03547973
Up Next Autoplay
EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
Category: Bladder Cancer
20 Views
Cancer-News 2 months
EV-103 Phase I Trial Presented at #ESMO19
EV-103 Phase I Trial Presented at #ESMO19
Category: Bladder Cancer
24 Views
Cancer-News 2 months
Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Category: Bladder Cancer
35 Views
Cancer-News 2 months
Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer
Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer
Category: Bladder Cancer
23 Views
Cancer-News 3 months
Strategies for Treating 2nd Line RCC Patients
Strategies for Treating 2nd Line RCC Patients
Category: Bladder Cancer
54 Views
obr 5 months
Treating Newly Diagnosed RCC Patients
Treating Newly Diagnosed RCC Patients
Category: Bladder Cancer
53 Views
obr 5 months
Data on Enfortumab in Post-Platinum and I-O Bladder Cancer
Data on Enfortumab in Post-Platinum and I-O Bladder Cancer
Category: Bladder Cancer
110 Views
obr 5 months
Combo Ipilimumab + Nivolumab in Histologies of Bladder Cancer
Combo Ipilimumab + Nivolumab in Histologies of Bladder Cancer
Category: Bladder Cancer
49 Views
obr 5 months
The Broad Implications of The SAUL Study
The Broad Implications of The SAUL Study
Category: Bladder Cancer
208 Views
Annual-Meeting 6 months